During the last session, Leap Therapeutics Inc (NASDAQ:LPTX)’s traded shares were 0.55 million, with the beta value of the company hitting 0.21. At the end of the trading day, the stock’s price was $3.35, reflecting an intraday gain of 4.04% or $0.13. The 52-week high for the LPTX share is $4.80, that puts it down -43.28 from that peak though still a striking 49.85% gain since the share price plummeted to a 52-week low of $1.68. The company’s market capitalization is $128.36M, and the average intraday trading volume over the past 10 days was 0.23 million shares, and the average trade volume was 368.19K shares over the past three months.
Leap Therapeutics Inc (LPTX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.25. LPTX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it.
Leap Therapeutics Inc (NASDAQ:LPTX) trade information
Leap Therapeutics Inc (LPTX) registered a 4.04% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.04% in intraday trading to $3.35, hitting a weekly high. The stock’s 5-day price performance is 12.42%, and it has moved by 20.07% in 30 days. Based on these gigs, the overall price performance for the year is -25.22%. The short interest in Leap Therapeutics Inc (NASDAQ:LPTX) is 1.01 million shares and it means that shorts have 2.68 day(s) to cover.
The consensus price target of analysts on Wall Street is $5.5, which implies an increase of 39.09% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5.5 and $5.5 respectively. As a result, LPTX is trading at a discount of -64.18% off the target high and -64.18% off the low.
Leap Therapeutics Inc (LPTX) estimates and forecasts
Statistics show that Leap Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Leap Therapeutics Inc (LPTX) shares have gone up 67.50% during the last six months, with a year-to-date growth rate more than the industry average at 53.77% against 16.80.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 28.36%. While earnings are projected to return 53.39% in 2025.
LPTX Dividends
Leap Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Leap Therapeutics Inc (NASDAQ:LPTX)’s Major holders
Leap Therapeutics Inc insiders own 17.29% of total outstanding shares while institutional holders control 40.30%, with the float percentage being 48.73%.
